Novo Nordisk: Sell-Off On CagriSema Data May Be Justified (NVO)
Dec 20, 2024 · Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in stock price. Learn more on NVO stock here.
OFF
Novo Nordisk: Sell-Off On CagriSema Data May Be Justified (NVO)
3 weeks from now
Dec 20, 2024 · Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in stock price. Learn more on NVO stock here.
seekingalpha.com
OFF
Novo Nordisk Stock Sees Biggest Loss In More Than 20 Years On …
3 weeks from now
Dec 20, 2024 · Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off …
yahoo.com
OFF
NVO Stock Plunges As Obesity Drug CagriSema Misses Target In …
3 weeks from now
Dec 23, 2024 · Despite the positive results, Novo Nordisk’s shares plunged 17.8% as the 22.7% weight loss, observed in patients treated with CagriSema in the phase III REDEFINE 1 study, …
yahoo.com
OFF
Novo Nordisk: Shares Look Fairly Valued After CagriSema …
3 weeks from now
Dec 20, 2024 · Novo Nordisk NVO disclosed top-line data from the phase 3 Redefine 1 study showing 20.4% placebo-adjusted weight loss for obesity drug candidate CagriSema after 68 …
morningstar.com
OFF
Novo Nordisk Stock Down On CagriSema Data, Lilly Up (NVO:NYSE)
3 weeks from now
Dec 20, 2024 · The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk had expected. Data wipes $125 billion from Novo's market value …
seekingalpha.com
OFF
Novo Nordisk: Shares Look Fairly Valued After... | Morningstar
3 weeks from now
Dec 20, 2024 · Novo Nordisk NVO disclosed top-line data from the phase 3 Redefine 1 study showing 20.4% placebo-adjusted weight loss for obesity drug candidate CagriSema after 68 …
morningstar.co.uk
OFF
Novo Nordisk Heads For Worst Day In 22 Years As New Obesity …
3 weeks from now
Dec 20, 2024 · Novo Nordisk shares plunged 18% Friday afternoon and were headed for their worst intraday drop since April 2002. However, retail investors have seemingly brushed off the …
stocktwits.com
OFF
NVO Stock Plunges As Obesity Drug CagriSema Misses Target In
3 weeks from now
Dec 23, 2024 · Additionally, Novo Nordisk reported that 40.4% of patients who received CagriSema after 68 weeks achieved a weight loss of 25% or more, compared to 6% with …
nasdaq.com
OFF
Weight Loss Seen With Novo’s CagriSema Weaker Than Expected
3 weeks from now
Dec 20, 2024 · BofA analyst Sachin Jain notes that Novo Nordisk (NVO) shares are down about 25%, which is "what we expected in this data scenario," as CagriSema weight loss data is not …
nasdaq.com
OFF
What Novo Nordisk’s Disappointing Trial Results Mean For The
3 weeks from now
Dec 20, 2024 · Novo reported that, in a late-stage study, a next-generation obesity drug called CagriSema led patients to lose 20% of their weight at 68 weeks when looking at all …
statnews.com
OFF
Novo Nordisk Sheds Billions In Value On Obesity Data
3 weeks from now
Dec 22, 2024 · Novo Nordisk emphasised an interpretation of the data, which assumed all subjects in the study adhered to treatment, that gave a weight reduction of 22.7% for …
pharmaphorum.com
OFF
Novo Nordisk Shares Drop 27% Premarket After Releasing …
3 weeks from now
Dec 20, 2024 · 06:01 EST Novo Nordisk (NVO) shares drop 27% premarket after releasing Cagrisema data Discover top-rated stocks from highly ranked analysts with Analyst Top …
businessinsider.com
OFF
Novo Nordisk Shares Plunge After CagriSema Obesity Drug Trial ...
3 weeks from now
Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its …
reuters.com
OFF
Novo Nordisk: Shares Look Fairly Valued After... | Morningstar
3 weeks from now
Dec 20, 2024 · Novo Nordisk NVO disclosed top-line data from the phase 3 Redefine 1 study showing 20.4% placebo-adjusted weight loss for obesity drug candidate CagriSema after 68 …
morningstar.ca
OFF
Novo Nordisk Sinks On Disappointing Trial Results For Next Gen …
3 weeks from now
Dec 20, 2024 · Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial. The new drug, CagriSema, led patients to lose …
yahoo.com
OFF
Why Novo Nordisk Stock Got Destroyed Today, But Eli Lilly And …
3 weeks from now
Dec 20, 2024 · Bad news for Novo Nordisk (NVO 0.34%) Friday was good news for Eli Lilly (LLY-0.24%) and Viking Therapeutics (VKTX 1.18%), its two main rivals in the field of weight loss …
fool.com
OFF
Novo Nordisk: A Rare Buying Opportunity (NYSE:NVO)
3 weeks from now
Dec 20, 2024 · As I'm writing these lines, Novo Nordisk A/S (NVO) is down about 16% on the pre-market session after the news came out that its obesity drug — CagriSema — delivered …
seekingalpha.com
OFF
Novo Nordisk Shares Plummet After Weight-loss Drug’s …
3 weeks from now
Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its …
nypost.com
OFF
Should You Buy The Dip In Novo Nordisk Stock Right Now?
3 weeks from now
2 days ago · Novo Nordisk recently announced results for a new weight loss candidate, CagriSema. Data from the trial underwhelmed investors, and Novo stock is down almost 20% …
fool.com
FAQs about Novo Nordisk: Sell-Off On CagriSema Data May Be Justified (NVO) Coupon?
Why did Novo Nordisk sell off on cagrisema?
Should you buy Novo Nordisk (NVO) GLP-1?
How did the cagrisema trial affect Novo Nordisk?
Will Novo Nordisk's cagrisema study strengthen its bullish case?
Why did Novo Nordisk's shares plunge 178%?
Should you buy Novo Nordisk A/S (NVO) stock?
Install CouponFollow Extension on Chrome
Install the CouponFollow extension to search for discount codes when shopping the fastest!
Install CouponFollow Chrome Extension
Listing Store by Characters
